公开(公告)号：US20090017014A1

公开(公告)日：2009-01-15

申请号：US12182090

申请日：2008-07-29

Applicant: Patricia A. Valdez ,  Austin L. Gurney ,  Iqbal Grewal

Inventor： Patricia A. Valdez ,  Austin L. Gurney ,  Iqbal Grewal

IPC: A61K39/395 ,  C07K14/00 ,  C07K19/00 ,  A61P37/04 ,  B65D85/00 ,  A61K38/16 ,  C07K16/46

CPC classification number: C07K14/47 ,  A61K39/00

Abstract: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases.

Abstract translation: 本发明涉及含有新蛋白质的组合物和使用这些组合物来诊断和治疗免疫相关疾病的方法。

公开(公告)号：US20060073146A1

公开(公告)日：2006-04-06

申请号：US11069473

申请日：2005-02-28

Applicant: Avi Ashkenazi ,  Kelly Dodge ,  Iqbal Grewal ,  Kyung Kim ,  Scot Marsters ,  Robert Pitti ,  Minhong Yan

Inventor： Avi Ashkenazi ,  Kelly Dodge ,  Iqbal Grewal ,  Kyung Kim ,  Scot Marsters ,  Robert Pitti ,  Minhong Yan

IPC: A61K39/395 ,  A61K38/17

CPC classification number: C07K14/525 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/52 ,  C07K16/2875 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/43

Abstract: Methods of using one or more agonists or antagonists to modulate activity of the members of the TNF and TNFR families referred to as TALL-1, APRIL, TACI, and BCMA are provided. The methods include in vitro, in situ, and/or in vivo diagnosis and/or treatment of mammalian cells or pathological conditions associated with TALL-1, APRIL, TACI, or BCMA, using one or more agonist or antagonist molecules. The methods of treatment disclosed by the invention include methods of treating immune related diseases and cancer.

Abstract translation: 提供了使用一种或多种激动剂或拮抗剂调节称为TALL-1，APRIL，TACI和BCMA的TNF和TNFR家族成员的活性的方法。 所述方法包括使用一种或多种激动剂或拮抗剂分子的体外，原位和/或体内诊断和/或治疗哺乳动物细胞或与TALL-1，APRIL，TACI或BCMA相关的病理状况。 本发明公开的治疗方法包括治疗免疫相关疾病和癌症的方法。

公开(公告)号：US20050031583A1

公开(公告)日：2005-02-10

申请号：US10129595

申请日：2002-02-06

Applicant: Iqbal Grewal

Inventor： Iqbal Grewal

IPC: C12N15/09 ,  A61K38/00 ,  A61K39/395 ,  A61K48/00 ,  A61P1/04 ,  A61P3/10 ,  A61P17/06 ,  A61P19/00 ,  A61P19/02 ,  A61P29/00 ,  A61P31/00 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  C07K14/705 ,  C12N5/06 ,  C12N5/08 ,  A61K38/20

CPC classification number: C07K14/70575 ,  A61K38/00 ,  A61K48/00

Abstract: Methods of stimulating or inhibiting activity of monocytes using OPG ligand, or other agonists or antagonists, are provided. Methods of treating pathological conditions, particularly immune related conditions, using such OPG ligand, agonists or antagonists are further provided. Agonists and antagonists contemplated for use in the invention include anti-RANK receptor antibodies, anti-OPG ligand antibodies, anti-OPG receptor antibodies, RANK receptor immunoadhesins, and OPG receptor immunoadhesins.

Abstract translation: 提供了使用OPG配体或其他激动剂或拮抗剂刺激或抑制单核细胞活性的方法。 进一步提供使用这种OPG配体，激动剂或拮抗剂治疗病理状况，特别是免疫相关病症的方法。 预期用于本发明的激动剂和拮抗剂包括抗RANK受体抗体，抗OPG配体抗体，抗OPG受体抗体，RANK受体免疫粘附素和OPG受体免疫粘附素。

公开(公告)号：US20140105860A1

公开(公告)日：2014-04-17

申请号：US14124565

申请日：2012-06-06

Applicant: Iqbal Grewal ,  Michael Gresser ,  Sanjay Khare ,  Rashid Syed

Inventor： Iqbal Grewal ,  Michael Gresser ,  Sanjay Khare ,  Rashid Syed

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395 ,  C07K14/525 ,  A61K38/19 ,  A61K38/21

CPC classification number: C07K16/2887 ,  A61K38/00 ,  A61K38/191 ,  A61K38/212 ,  A61K39/39558 ,  A61K45/06 ,  C07K14/525 ,  C07K2319/00

Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to engineered fusion molecules comprising an antibody (Ab) which can target tumor cells (e.g., RITUXIN®), fused to one or more biologic moieties capable of inducing apoptosis in tumor cells, e.g., tumor necrosis factor super family (TNFSF) member ligands such as TNF-α, CD40L, CD95L (also “FasL/Apo-1L”) and TRAIL/Apo-2L. Importantly, the engineered fusion molecules of the present invention retain the death-inducing properties of the biologic moiety at optimum concentrations and with reduced systemic toxicities, thus improving the therapeutic index of the engineered fusion molecules.

Abstract translation: 本发明的领域涉及基因工程融合分子，制备所述融合分子的方法及其在抗肿瘤免疫治疗中的用途。 更具体地，本发明涉及包含能够靶向肿瘤细胞的抗体（Ab）的工程化融合分子，所述抗体（例如RITUXIN？）与一个或多个能诱导肿瘤细胞凋亡的生物部分融合，例如肿瘤坏死因子超级 家族（TNFSF）成员配体如TNF-α，CD40L，CD95L（也称为“FasL / Apo-1L”）和TRAIL / Apo-2L。 重要的是，本发明的工程化融合分子将生物部分的死亡诱导性质保持在最佳浓度并具有降低的全身毒性，从而改善了工程化融合分子的治疗指数。

公开(公告)号：US20110123531A1

公开(公告)日：2011-05-26

申请号：US13019183

申请日：2011-02-01

Applicant: Iqbal GREWAL

Inventor： Iqbal GREWAL

IPC: A61K39/395 ,  A61P35/00

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2887 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/76

Abstract: The invention provides for the treatment of diseases or disorders characterized by cells expressing the CD40 membrane glycoprotein. The invention provides methods for the treatment of various diseases or disorders characterized by cells expressing CD40 with a combination of an agent causes the depletion of cells expressing CD40 and a second agent which causes the depletion of cells expressing the CD20 membrane antigen. Pharmaceutical compositions and articles of manufacture such as kits comprising the agents and combinations thereof are also provided.

Abstract translation: 本发明提供治疗以表达CD40膜糖蛋白的细胞为特征的疾病或病症。 本发明提供了治疗各种疾病或病症特征的方法，其特征在于表达CD40细胞的细胞与药物的组合导致表达CD40的细胞的消耗，以及引起表达CD20膜抗原的细胞消耗的第二药剂。 还提供药物组合物和制品，例如包含试剂及其组合的试剂盒。

公开(公告)号：US20080305106A1

公开(公告)日：2008-12-11

申请号：US11568901

申请日：2005-04-12

Applicant: Jane Brennan ,  Frederic J. de Sauvage ,  Ellen Filvaroff ,  Iqbal Grewal ,  Bryan Irving ,  Jagath Reddy Junutula ,  Daniel Kirchhofer ,  Franklin Peale ,  Heide Phillips ,  Tracy Tang ,  Dineli Wickramasinghe ,  Weilan Ye

Inventor： Jane Brennan ,  Frederic J. de Sauvage ,  Ellen Filvaroff ,  Iqbal Grewal ,  Bryan Irving ,  Jagath Reddy Junutula ,  Daniel Kirchhofer ,  Franklin Peale ,  Heide Phillips ,  Tracy Tang ,  Dineli Wickramasinghe ,  Weilan Ye

IPC: A61K39/395 ,  C12Q1/68 ,  C12N5/06 ,  A61K38/00 ,  A61P19/00 ,  A61P27/00 ,  A01K67/027 ,  C07K16/18

CPC classification number: A01K67/0275 ,  A01K67/0278 ,  A01K2217/05 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A61K49/0008 ,  C07K14/4703 ,  C07K14/705 ,  C12N15/8509

Abstract: The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO256, PRO34421, PRO334, PRO770, PRO983, PRO1009, PRO1107, PRO1158, PRO1250, PRO1317, PRO4334, PRO4395, PRO49192, PRO9799, PRO21175, PRO19837, PRO21331, PRO23949, PRO697 or PRO1480 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

Abstract translation: 本发明涉及转基因动物，以及与基因功能表征相关的组合物和方法。 具体地，本发明提供转基因小鼠，其包括PRO256，PRO34421，PRO334，PRO770，PRO983，PRO1009，PRO1107，PRO1158，PRO1250，PRO1317，PRO4334，PRO4395，PRO49192，PRO9799，PRO21175，PRO19837，PRO21331，PRO23949，PRO697或PRO1480中的中断 基因。 这样的体内研究和表征可以提供有用的识别和发现治疗和/或治疗用于预防，改善或矫正与基因中断相关的疾病或功能障碍如神经障碍; 心血管，内皮或血管生成障碍; 眼睛异常; 免疫学障碍; 肿瘤疾病; 骨代谢异常或障碍; 脂代谢紊乱 或发育异常。

公开(公告)号：US07393532B1

公开(公告)日：2008-07-01

申请号：US10088950

申请日：2000-10-18

Applicant: Frederic J. de Sauvage ,  Iqbal Grewal ,  Austin L. Gurney

Inventor： Frederic J. de Sauvage ,  Iqbal Grewal ,  Austin L. Gurney

IPC: A61K39/395 ,  A61K39/00

CPC classification number: A61K39/0005 ,  A61K39/00 ,  A61K2039/57 ,  Y02A50/41

Abstract: The present invention relates to methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to methods for biasing the differentiation of T-cells in either the Th1 subtype or the Th2 subtype, based on the relative expression levels of the gene TCCR, and its agonists or antagonists. The present invention further relates to a method of diagnosing Th1- and Th2-mediated diseases.

Abstract translation: 本发明涉及用于治疗和诊断免疫相关疾病的方法，包括由主要以Th1或Th2细胞响应于抗原刺激释放的细胞因子介导的那些。 本发明还涉及基于TCCR及其激动剂或拮抗剂的相对表达水平来偏置Th1亚型或Th2亚型中T细胞分化的方法。 本发明还涉及诊断Th1-和Th2介导的疾病的方法。

公开(公告)号：US20050271658A1

公开(公告)日：2005-12-08

申请号：US11120338

申请日：2005-05-03

Applicant: Paul Brunetta ,  Iqbal Grewal ,  Patricia Walicke

Inventor： Paul Brunetta ,  Iqbal Grewal ,  Patricia Walicke

IPC: A61K39/395 ,  C07K16/28

CPC classification number: C07K16/2887 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/72

Abstract: The present application describes a method of preventing an autoimmune disease in an asymptomatic human subject at risk for experiencing one or more symptoms of the autoimmune disease, by administering a CD20 antibody to the subject in an amount to prevent the subject from experiencing one or more symptoms of the autoimmune disease.

Abstract translation: 本申请描述了通过向受试者施用防止受试者体验一种或多种症状的量的CD20抗体来预防患有经历自身免疫性疾病的一种或多种症状风险的无症状人类受试者的自身免疫性疾病的方法 的自身免疫性疾病。

公开(公告)号：US09534056B2

公开(公告)日：2017-01-03

申请号：US14124565

申请日：2012-06-06

Applicant: Iqbal Grewal ,  Michael Gresser ,  Sanjay Khare ,  Rashid Syed

Inventor： Iqbal Grewal ,  Michael Gresser ,  Sanjay Khare ,  Rashid Syed

IPC: C07K19/00 ,  C07K14/525 ,  C07K16/28 ,  A61K38/19 ,  A61K38/21 ,  A61K39/395 ,  A61K45/06 ,  C07K14/475 ,  A61K38/00

CPC classification number: C07K16/2887 ,  A61K38/00 ,  A61K38/191 ,  A61K38/212 ,  A61K39/39558 ,  A61K45/06 ,  C07K14/525 ,  C07K2319/00

Abstract: The field of the present invention relates to genetically engineered fusion molecules, methods of making said fusion molecules, and uses thereof in anti-tumor immunotherapies. More specifically, the present invention relates to engineered fusion molecules comprising an antibody (Ab) which can target tumor cells (e.g., RITUXIN®), fused to one or more biologic moieties capable of inducing apoptosis in tumor cells, e.g., tumor necrosis factor super family (TNFSF) member ligands such as TNF-α, CD40L, CD95L (also “FasL/Apo-1L”) and TRAIL/Apo-2L. Importantly, the engineered fusion molecules of the present invention retain the death-inducing properties of the biologic moiety at optimum concentrations and with reduced systemic toxicities.

Abstract translation: 本发明的领域涉及基因工程融合分子，制备所述融合分子的方法及其在抗肿瘤免疫治疗中的用途。 更具体地，本发明涉及包含能够靶向肿瘤细胞的抗体（Ab）的工程化融合分子，所述抗体（例如RITUXIN？）与一个或多个能诱导肿瘤细胞凋亡的生物部分融合，例如肿瘤坏死因子超级 家族（TNFSF）成员配体如TNF-α，CD40L，CD95L（也称为“FasL / Apo-1L”）和TRAIL / Apo-2L。 重要的是，本发明的工程改造的融合分子将生物部位的死亡诱导性质保持在最佳浓度和降低的全身毒性。

公开(公告)号：US20110097325A1

公开(公告)日：2011-04-28

申请号：US12437452

申请日：2009-05-07

Applicant: Frederic J. de Sauvage ,  Iqbal Grewal ,  Austin L. Gurney

Inventor： Frederic J. de Sauvage ,  Iqbal Grewal ,  Austin L. Gurney

IPC: A61K39/395 ,  C12N5/0783 ,  A61K31/7105 ,  A61K38/00 ,  G01N33/53 ,  A61K31/711 ,  A61P37/02 ,  A61P31/04 ,  A61P31/10

CPC classification number: C07K14/715 ,  A01K2217/075 ,  A61K38/00 ,  Y02A50/41

Abstract: The present invention relates to methods for the treatment and diagnosis of immune related diseases, including those mediated by cytokines released primarily either Th1 or Th2 cells in response to antigenic stimulation. The present invention further relates to methods for biasing the differentiation of T-cells in either the Th1 subtype or the Th2 subtype, based on the relative expression levels of the gene TCCR, and its agonists or antagonists. The present invention further relates to a method of diagnosing Th1- and Th2-mediated diseases.

Abstract translation: 本发明涉及用于治疗和诊断免疫相关疾病的方法，包括由主要以Th1或Th2细胞响应于抗原刺激释放的细胞因子介导的那些。 本发明还涉及基于TCCR及其激动剂或拮抗剂的相对表达水平来偏置Th1亚型或Th2亚型中T细胞分化的方法。 本发明还涉及诊断Th1-和Th2介导的疾病的方法。